Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Prostate Cancer

Free Subscription Articles published in Int J Radiat Oncol Biol Phys Retrieve available abstracts of 219 articles: HTML format

Single Articles

January 2022
1. RAMAN S, Keyes M, Oh J, Rousseau E, et al
   Patterns of prostate cancer recurrence after brachytherapy determined by PSMA PET/CT imaging.
   Int J Radiat Oncol Biol Phys. 2022 Jan 2. pii: S0360-3016(21)03437.
   PubMed     Abstract available
   
   
   
2. GLICKSMAN RM, Berlin A
   FACE Value of Patient-Reported Outcomes in Dose-Escalated Radiation Therapy for Prostate Cancer.
   Int J Radiat Oncol Biol Phys. 2022;112:93-95.
   PubMed    
   
   
   
3. HALL WA, Deshmukh S, Bruner DW, Michalski JM, et al
   Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126.
   Int J Radiat Oncol Biol Phys. 2022;112:83-92.
   PubMed     Abstract available
   
   
   December 2021
4. ROY S, Zaorsky NG, Bagshaw HP, Berlin A, et al
   An Expert Review on the Combination of Relugolix with Definitive Radiation Therapy for Prostate Cancer.
   Int J Radiat Oncol Biol Phys. 2021 Dec 16. pii: S0360-3016(21)03240.
   PubMed     Abstract available
   
   
   November 2021
5. ZAORSKY NG, Spratt DE
   Elective Nodal Radiotherapy for Prostate Cancer: For None, Some, or all?
   Int J Radiat Oncol Biol Phys. 2021;111:965-967.
   PubMed    
   
   
   
6. ROY S, Spratt DE, Morgan SC, Zhou M, et al
   Association of Short-term Patient-reported Outcomes with Long-term Oncologic Outcomes in Localized Prostate Cancer Patients Treated with Radiotherapy and ADT in a Randomized Controlled Trial.
   Int J Radiat Oncol Biol Phys. 2021 Nov 14. pii: S0360-3016(21)03118.
   PubMed     Abstract available
   
   
   
7. HANNAN R, Salamekh S, Desai NB, Garant A, et al
   Stereotactic Ablative Radiotherapy for High-Risk Prostate Cancer-a Prospective Multi-level MRI-based Dose Escalation Trial.
   Int J Radiat Oncol Biol Phys. 2021 Nov 10. pii: S0360-3016(21)03047.
   PubMed     Abstract available
   
   
   
8. SINZABAKIRA F, Heemsbergen WD, Pos F, Incrocci L, et al
   Patient-reported outcomes in the acute phase of the randomized hypofractionated irradiation for prostate cancer (HYPRO) trial.
   Int J Radiat Oncol Biol Phys. 2021 Nov 2. pii: S0360-3016(21)03049.
   PubMed     Abstract available
   
   
   
9. ENNIS RD, Vapiwala N
   The Fallacy of the Consultation and Informed Consent Process in Radiation Oncology Through the Lens of Prostate Cancer.
   Int J Radiat Oncol Biol Phys. 2021;111:643-646.
   PubMed    
   
   
   
10. JASSAR H, Tai A, Chen X, Keiper T, et al
    Real-Time Motion Tracking Based on Orthogonal Cine MRI During MR-Guided Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
11. CHEN GP, Tai A, Omari EA, Bedi M, et al
    Real-Time Motion Tracking and Correction During Tomotherapy for Prostate Cancer: Impact of Fiducial Migration.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
12. BRENNEMAN RJ, Andruska N, Roy A, Waters MR, et al
    Characterization of a Novel Radiopaque Perirectal Hydrogel Spacer for Prostate Cancer Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
13. WU TC, Xiang M, Nickols NG, Tenn SE, et al
    Prostate-Centric vs. Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer With Simultaneous Integrated Boost: A Dosimetric Comparison.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
14. TAKAGI M, Hasegawa Y, Tateoka K, Takada Y, et al
    Dosimetric Study of Proton Therapy Using Scanning Method for Localized Prostate Cancer Patients in Comparison With Wobbler Method and Volumetric-Modulated Arc Therapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
15. GALLITTO M, Mayeda M, Hwang ME, Rayn K, et al
    Factors Contributing to Bladder Filling Variability in Patients Receiving Radiotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
16. SONG Y, Ko WC, Tamas P, Hsu HY, et al
    Effects of Bladder Filling and Rectal Gas on Number of CBCT Scans and Treatment Time for Prostate Cancer Patients Undergoing EBRT.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
17. CARRASQUILLA M, O'Connor T, Zwart A, Danner M, et al
    Safety and Early Efficacy of Involved Field SBRT for Nodal Oligo-Recurrent Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
18. POWELL A, Goldstein JP, Lucas ER, Long J, et al
    The Association Between Use of Hypofractionated Radiation Therapy for the Treatment of Prostate Cancer and Treatment Completion.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
19. BATES JE, Sanders T, Arnone A, Elmore SNC, et al
    Geographic Density of Linear Accelerators and Receipt of Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
20. KOWALCHUK RO, Breen W, Harmsen WS, Jeans E, et al
    Cost-Effectiveness of Treatment Strategies for High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
21. DEE EC, Taunk NK, Deville C Jr, Mahal BA, et al
    Trends in Receipt of Shorter Regimens of Radiation Therapy and Treatment Noncompletion Disparities Among Breast and Prostate Cancer Patients in the United States.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
22. JOOYA A, Qureshi D, Leigh J, Webber C, et al
    Barriers to Access Palliative Radiotherapy in Prostate Cancer - A Population-Based Study.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
23. MEEM M
    Dose-Escalated External-Beam Radiation to Prostate and Pelvic Nodes in High-Risk Prostate Cancer: Long-Term Toxicities and Outcomes at a Tertiary Center.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
24. KRUGER J, Bylund KC, Cummings MA, Frye T, et al
    Role of Pelvic Radiation in Management of Non-Metastatic Pathological Node-Positive Prostate Cancer: A Single Institution Experience.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
25. ZAPATERO A, Castro P, Roch M, Buchser D, et al
    VMAT Focal Boost to MRI-Defined Intraprostatic Lesion in Localized Prostate Cancer: Results of a Phase II Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
26. YOON JJ, Sayan M, Wang SJ, Watts A, et al
    Effect of Hydrogel Rectal Spacer on Intrafraction Prostate Motion During Radiotherapy of Prostate Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
27. WILLEN B, Krauss DJ, Nandalur SR, Ye H, et al
    High Dose Rate Brachytherapy as Monotherapy vs. External Beam With HDR Boost in Unfavorable Intermediate Risk Localized Prostate Cancer: A Matched-Pair Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
28. WEG ES, Holt SK, Elia M, Schade G, et al
    Assessing the Risk of Pathologic Lymph Node Involvement in Intermediate Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
29. TRAN PT, Berlin A, Siva S, Reynders D, et al
    Individual Patient Level Meta-Analysis of Prospective Trials Studying Metastasis-Directed Therapy for Metachronous Oligometastatic Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
30. SUTERA P, Van der Eecken K, Kishan AU, Hamid A, et al
    Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
31. SMITH CP, Xiang M, Armstrong WR, Nickols NG, et al
    Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post-Hoc Analysis of Two Prospective Ga-68-PSMA PET/CT Imaging Trials.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
32. SHULMAN RM, Wong JK, Handorf E, Salama JK, et al
    Dosimetric Predictors of Toxicity in Patients With Early-Stage Prostate Cancer Treated With Moderately Hypofractionated IMRT or PBT: A Multi-Institutional Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
33. SHABSOVICH D, Xiang M, Katz AW, Mantz CA, et al
    Patterns and Predictors of Distant Failure After Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Retrospective Multi-Institutional Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
34. SANDOVAL ML, Latifi K, Parsee A, Andreozzi J, et al
    Defining MR-Based Parameters of Treatment Response to Immune-Modulatory Therapy for Grade Group 5 Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
35. QI X, Gao XS
    Radiotherapy of the Primary Tumor and All Metastatic Lesions in Synchronous Oligometastatic Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
36. PAPANIKOLAOU P, Swanson GP, Stathakis S, Fakhreddine M, et al
    Estimation of Dose-Response Correlations Regarding Significant Blood Count Drops After Radiotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
37. ONAL C, Kose F, Ozyigit G, Aksoy S, et al
    Stereotactic Body Radiotherapy for Oligoprogressive Lesions in Metastatic Castration-Resistant Prostate Cancer Patients During Abiraterone/Enzalutamide Treatment.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
38. ONAL C, Ozyigit G, Oymak E, Guler OC, et al
    Stereotactic Radiotherapy to Oligoprogressive Lesions Detected With (68)Ga-PSMA-PET/CT in Castration-Resistant Prostate Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
39. OLSON AC, Skiba JH, Gill BS, Wang H, et al
    A Prospective, Single-Arm, Phase II, Multi-Center Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
40. NIHEI K, Nakamura K, Karasawa K, Saito Y, et al
    A Japanese Multi-Institutional Phase II Study of Moderate Hypofractionated Intensity-Modulated Radiotherapy With Image-Guided Technique for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
41. NAVARRO I, Joseph L, Liu Z, Berlin A, et al
    Physician and Patient Reported Morbidity After MR-Guided Salvage Brachytherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
42. MONINGI S, Johnson HK, Peng LC, Leeman JE, et al
    Could an Academic Review of Pathology Lead to Changes in Patient Care in Men With Prostate Cancer?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
43. MISZCZYK M, Jablonska I, Krzysztofiak T, Magrowski L, et al
    Does Brachytherapy Boost Improve Biochemical Control in Intermediate and High-Risk Prostate Cancer Patients Compared to External Beam Radiotherapy Alone?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
44. MCDONALD AM, DeMora L, Lenzie A, Hoyle J, et al
    Body Composition and Risk of All-Cause Mortality in Men Treated With Radiation Therapy for Prostate Cancer: A Pooled Analysis of NRG/RTOG 9406 and NRG/RTOG 0126.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
45. MA W, Tao W, Hara D, Shi J, et al
    The Dual Effect of the HDAC Inhibitor Romidepsin on Androgen Receptor Signaling and DNA Damage Repair in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
46. MA TM, Roy S, Mantz CA, Fuller DB, et al
    Working Towards a New Definition of Biochemical Failure in the Era of Stereotactic Body Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
47. LIN EY, Lee A, Demanes J, Kamrava M, et al
    High-Dose Rate (HDR) Brachytherapy is a Safe and Effective Treatment for Prostate Cancer Patients With Prior Transurethral Resection of the Prostate (TURP).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
48. KOONTZ BF, Hoffman KE, Oyekunle T, George DJ, et al
    Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
49. KERNS SL, Morlang A, Lee SM, Hall WA, et al
    Use of Angiotensin Converting Enzyme Inhibitors and Risk of Late Bladder Toxicity Following Radiotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
50. KAMRAN SC, Aldrighetti C, Oladeru OT, Niemierko A, et al
    Impact of the COVID-19 Pandemic on Prostate Cancer Radiotherapy Practice Patterns: A Northeast Regional Longitudinal Survey Study.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
51. JENSEN GL, Hammonds K, Jhavar SG, Swanson GP, et al
    Functional Outcomes With Dose-Escalated, Conventionally Dosed, or Without Nodal Irradiation in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
52. JAWORSKI E, Fang F, Gharzai LA, McFarlane M, et al
    Utility of Long-Term Follow-Up to Determine Safety in Radiotherapy-Specific Trials for Localized Prostate Cancer: Meta-Analysis of 29 Randomized Trials.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
53. HUTTEN R, Parsons MW, Khouri A, Tward A, et al
    The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
54. HASKINS C, Siddiqui OM, Lin JY, Bentzen SM, et al
    Rectal Volume and Quality of Life in Prostate Cancer Patients Receiving Pediococcus-Based Probiotics and Radiation Therapy: A Prospective Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
55. HAAS JA, Mendez C, Katz A, Witten MR, et al
    Robotic SBRT in Prostate Cancer Patients Younger Than 50 Years Old.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
56. GOROVETS D, Tin A, Vickers AJ, Zelefsky MJ, et al
    Patient-Reported Financial Toxicity Following Definitive Radiation Therapy for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
57. GLICKSMAN R, Kishan AU, Katz AJ, Mantz CA, et al
    4-Year PSA Response Rate as a Predictive Measure in Intermediate Risk Prostate Cancer Treated With Ablative Therapies: The Sprat Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
58. LALLA VD, Elakshar S, Anidjar M, Bahoric B, et al
    Salvage External Beam Radiotherapy After HIFU Failure in Localized Prostate Cancer: A Single Institution Experience.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
59. DHERE VR, Fischer-Valuck BW, Goyal S, Liu Y, et al
    Toxicity Outcomes After Low-Dose-Rate vs. High-Dose-Rate Brachytherapy Boost in Combination With External Beam Radiation for Intermediate and High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
60. DHERE VR, Schuster DM, Goyal S, Schreibmann E, et al
    Randomized Trial of Conventional vs Conventional Plus Fluciclovine ((18)F) PET/CT-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer: Volumetric and Patient-Reported Toxicity Analyses.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
61. DELGADILLO R, Spieler B, Deana A, Ford J, et al
    Cone Beam CT Based Delta-Radiomics of Prostate Cancer Patients and Their Correlation to Quality of Life, Genitourinary and Gastrointestinal Toxicities.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
62. DEE EC, Muralidhar V, King MT, Martin NE, et al
    Association Between Treatment Modality and Probability of Second Malignancy in Localized Prostate Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
63. CORKUM MT, Morton G, Loblaw DA, Tseng CL, et al
    A Prospective Study of MR-Guided Focal Salvage High Dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: Updated Results of 30 Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
64. CHIRILA ME, Brausi M, Chatterjee P, Gordon K, et al
    Salvage Treatments for the Local Recurrence of Prostate Cancer After Radiotherapy - Results of an International Multidisciplinary Survey.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
65. CHEUNG P, Tseng CL, Chung HR, Chu W, et al
    Intermittent Androgen Deprivation Therapy Plus Comprehensive Stereotactic Radiotherapy for Oligometastatic Prostate Cancer (CROP).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
66. CHAPMAN D, Quinn TJ, Hamstra DA
    Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
67. BRYANT CM, Henderson RH, Mendenhall WM, Nichols RC Jr, et al
    10-Year Outcomes Following Proton Therapy for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
68. BHANGOO RS, DeWees TA, Thorpe CS, Petersen M, et al
    Updated Toxicity and Quality-of-Life Outcomes From a Randomized Phase III Trial of Extreme Hypofractionated vs. Standard Fractionated Proton Therapy for Low-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
69. BERGHEN C, Joniau S, Rans K, Poels K, et al
    Metastasis-Directed Therapy for Oligoprogressive Castration-Resistant Prostate Cancer - Preliminary Results of the Prospective, Single-Arm MEDCARE Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
70. AZGHADI S, Abdelhafez Y, Parikh M, Stephen M, et al
    Detectability Rates and Impact on Management From High-Sensitivity Total-Body (18)F-Fluciclovine PET/CT Scans in Patients With Prostate Cancer Biochemical Recurrence.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
71. ANDRUSKA N, Diaz EJ, Gay HA, Agabalogun T, et al
    Can EBRT Dose-Escalation Above 80 Gy Yield Comparable Survival Rates Relative to EBRT Plus Brachytherapy Boost in Men With Unfavorable Intermediate-Risk Prostate Cancer?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
72. AGABALOGUN T, Andruska N, Fischer-Valuck BW, Gay HA, et al
    Comparative Effectiveness of the Brachytherapy Boost and Androgen Deprivation Therapy for African-American Men with Unfavorable Intermediate-Risk Prostate Cancer Treated With External Beam Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
73. CHEBRA I
    Apoptosis and Senescence in Localized Prostate Cancer Tissues Treated With HDR-BT Boost With Radiotherapy (EBRT) and ADT.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
74. HARA D, Shi J, Tao W, Ma W, et al
    Impact of PSMA Targeted Gold Nanoparticles on Prostate Cancer Radiation Bystander Effect.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
75. RAJKUMAR AW, Wang J, Chennupati DV, Kirschner AN, et al
    Optimizing STING Activity in Prostate Cancer Pre-Clinical Models.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
76. FAIELLA A, Palermo B, Bottero M, Panetta M, et al
    Immunomonitoring During Radiotherapy of Prostate Cancer: Effect of Dose & Volume on Peripheral Immune Cells.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
77. CHEBRA I
    Effects of Androgen Deprivation Therapy (ADT) Combined With Radiotherapy (EBRT) and HDR-BT Boost on DNA Repair Markers in Prostate Carcinoma.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
78. CANTALINO JM, Singh T, Zwart A, Danner M, et al
    Ejaculatory Function Following Stereotactic Body Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
79. GEWANTER RM, Gross J, Mazzarella K, Urban J, et al
    Does the I-PSS Accurately Assess Urinary Function in Prostate Cancer Patients? Evidence From a Study of Nursing Verification of Patient Answers.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
80. CRUICKSHANK I, Deville C Jr, Chen H, Halthore AN, et al
    Comparative In Silico Analysis of Intensity Modulated Scanning Beam Proton Therapy (IMPT) and Volumetric Modulated Arc Photon Radiotherapy (VMAT) for the Post-Operative Treatment of Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
81. ZHU S, Elshaikh MA, Movsas B, Wen N, et al
    Automatic Prediction of 3D Radiation Dose Distribution in Prostate Cancer Treated with Volumetric Modulated Arc Therapy (VMAT) Using a Conditional Generative Adversarial Network (cGAN).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
82. SURESH R, Niemela J, Akram S, Valdman A, et al
    A Comparative Study Between AI-Generated, Real-Life Clinical as Well as Reference Rectal Volumes Defined in Accordance With the Swedish National STRONG Guidelines in Prostate Cancer Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
83. DUAN J, Bernard ME, Downes L, Clair WS, et al
    A Double-Blind Study to Evaluate the Feasibility of Using AI-Powered Auto-Segmentation in Prostate Cancer Treatment.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
84. BOYD GH, Efstathiou JA, Kamran SC, Zietman AL, et al
    Qualitative and Quantitative Analysis of a Deep Learning Auto Contouring Model for Radiotherapy in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
85. MURAKAMI Y, Soyano T, Kozuka T, Ushijima M, et al
    Can Dosiomics Features Be Relevant Predictive Factors for Biochemical Recurrence After Radiotherapy in Prostate Cancer Patients?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
86. YANG F, Ghosh S, Yee D, Patel SI, et al
    Conventional vs. Hypofractionation Radiation for High-Risk Prostate Cancer Patients (CHIRP): 24 Months Patient-Reported Quality of Life Outcomes of the Randomized Phase II CHIRP Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
87. DESS RT, Sun Y, Bolla M, Zapatero A, et al
    Prognostic and Predictive Performance of Routine Clinicopathologic Variables in 10,535 Men Enrolled on Randomized Phase III Trials in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
88. KISHAN AU, Romero T, Wang X, Pisansky TM, et al
    Impact of High DosE rAdioTherapy (HEAT) in Localized Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis of 15 Randomized Trials.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
89. KWOK Y, Mirkheshti N, Naslund M, Hussain A, et al
    A Prospective Trial of Aggressive Therapy Consisting of Neoadjuvant Chemotherapy and Androgen Deprivation Followed by Prostatectomy and Adjuvant Radiation in High/Very High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
90. ZAPATERO A, Grande ADG, Maldonado X Sr, Alvarez A, et al
    10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
91. KISHAN AU, Wong JK, Merrick GS, Tran PT, et al
    The Relationship Between Androgen Deprivation Therapy Duration and External Beam Radiotherapy With or Without a Brachytherapy Boost in High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
92. MALONE S, Spratt DE, Morgan SC, Grimes S, et al
    Association of Short-Term Patient-Reported Outcomes With Long-Term Oncologic Outcomes in Localized Prostate Cancer Treated With Radiotherapy and ADT in a Phase III Randomized Controlled Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
93. ROY S, Morgan SC, Spratt DE, Grimes S, et al
    Association of Baseline Health-Related Quality of Life Metrics With Outcome in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
94. DE B, Pasalic D, Barocas DA, Zhao Z, et al
    Five-Year Outcomes From a Prospective Comparative Effectiveness Study Evaluating External Beam Radiotherapy With Low Dose-Rate Brachytherapy Boost and Prostatectomy for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
95. KATZ A, Cao Y, Shen X, Usinger DS, et al
    Associations Between Knowledge of Others' Experiences and Patient Perceptions of Treatments for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
96. BOYAJIAN R, Gordon WJ, Kowtoniuk AM, Boyajian KR, et al
    Development & Impact of a Virtual PSA Monitoring Clinic for Follow-up of Prostate Cancer Patients: An Efficient Model With Unique Benefits Relevant to COVID-19.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
97. CONDE-MORENO AJ, Lopez F, Hervas A, Morillo V, et al
    Phase II Trial of SBRT and Androgen Deprivation for Oligometastases in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
98. GAUDREAULT M, Chang D, Hardcastle N, Jackson P, et al
    Evaluation of PSMA-PET Biology-Guided Radiotherapy Sequential Boost to the PSMA-avid Subvolume in the Prostate Region in Low-Volume Advanced Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
99. MA TM, Xiang M, Tilki D, Karnes RJ, et al
    Prognostic Significance of the Risk of Non-localized Disease on PSMA/PET: Comparative Performance of a Novel, PSMA/PET-Derived Risk Stratification Tool for High-Risk Prostate Cancer in a Large, Multi-Institutional Cohort.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
100. HAMMER L, Jiang R, Hearn JWD, Dess RT, et al
     A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) Prior to Radical Prostatectomy (RP) in Locally Advanced Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
101. NGUYEN PL, Huang HC, Davicioni E, Sandler HM, et al
     Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
102. KISHAN AU, Sun Y, Pisansky TM, Bolla M, et al
     Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium: Impact of Androgen Deprivation Therapy Use and Duration With Definitive Radiotherapy for Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
103. DAI Z, Jambor I, Taimen P, Pantelic M, et al
     Accurate Prostate Cancer Detection and Segmentation Using Non-Local Mask R-CNN With Histopathological Ground Truth.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
104. KANWAR A, Claunch C, Rana S, Merz B, et al
     Evaluation of Commercial Pelvic Autosegmentation Solutions in Anatomic Edge Cases of Patients Receiving Definitive Radiotherapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
105. MOVSAS B, Rodgers J, Elshaikh MA, Martinez AA, et al
     Dose Escalated Radiotherapy (RT) Alone or in Combination With Short-Term Total Androgen Suppression (TAS) for Intermediate Risk Prostate Cancer: Patient Reported Outcomes (PROs) From the NRG Oncology/RTOG 0815 Randomized Trial.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
106. SPIELER B, Khodor Y, Chakrabortty S, Fischer C, et al
     Plasma Exosomal RNA Biomarkers of High-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
107. GLICKSMAN R, Liu SK, Cheung P, Vesprini D, et al
     Elective Nodal Ultra Hypofractionated Radiation for Prostate Cancer: Safety and Efficacy From Four Prospective Clinical Trials.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
108. PADAYACHEE J, Sanmamed N, Lee J, Liu Z, et al
     Local Control in Tumor-Targeted Dose Escalation for Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
109. YAMOAH K, Lee KM, Alba PR, Awasthi S, et al
     Defining Racial Disparities Across the Prostate Cancer Disease Continuum in an Equal Access-to-Care Setting Within the Nation's Largest Healthcare Network.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
110. GLICKSMAN R, Loblaw DA, Morton G, Szumacher E, et al
     Elective Pelvic Nodal Irradiation With A Simultaneous Hypofractionated Integrated Prostate Boost for Localized High Risk Prostate Cancer: Long Term Results From a Prospective Clinical Trial.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
111. SALERNO KE, Turkbey B, Lindenberg L, Mena E, et al
     Detection of Failure Patterns Using Advanced Imaging in Patients With Biochemical Recurrence Following Low Dose Rate Brachytherapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
112. KRAUSS DJ, Karrison TG, Martinez AA, Morton G, et al
     Dose Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Suppression for Intermediate Risk Prostate Cancer: Outcomes From the NRG Oncology/RTOG 0815 Randomized Trial.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     October 2021
113. MUSUNURU HB, Cheung P, Vesprini D, Liu SK, et al
     Gantry-based 5-fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes from 2 Prospective Studies comparing SABR Boost with MR Dose Painted HDR Brachytherapy Boost.
     Int J Radiat Oncol Biol Phys. 2021 Oct 9. pii: S0360-3016(21)02899.
     PubMed     Abstract available
     
     
     September 2021
114. JONES CU, Pugh SL, Sandler HM, Chetner MP, et al
     Adding short-term androgen deprivation therapy to RT in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial.
     Int J Radiat Oncol Biol Phys. 2021 Sep 1. pii: S0360-3016(21)02724.
     PubMed     Abstract available
     
     
     
115. NAGAR H, Spratt DE
     Prostate SBRT Dose Escalation (9 Gyx5, 13.3 Gyx3, 24 Gyx1): Are We Making Progress?
     Int J Radiat Oncol Biol Phys. 2021;111:110-112.
     PubMed    
     
     
     August 2021
116. NUIJENS AC, Oei AL, van Oorschot B, Visser J, et al
     Gamma-H2AX Foci Decay Ratio as a Stronger Predictive Factor of Late Radiation Toxicity than Dose-Volume Parameters in a Prospective Cohort of Prostate Cancer Patients.
     Int J Radiat Oncol Biol Phys. 2021 Aug 19. pii: S0360-3016(21)02708.
     PubMed     Abstract available
     
     
     
117. MURAKAMI Y, Soyano T, Kozuka T, Ushijima M, et al
     Dose-based radiomic analysis (dosiomics) for intensity-modulated radiotherapy in patients with prostate cancer: Correlation between planned dose distribution and biochemical failure.
     Int J Radiat Oncol Biol Phys. 2021 Aug 5. pii: S0360-3016(21)02627.
     PubMed     Abstract available
     
     
     
118. FERREIRA MR, Sands CJ, Li JV, Andreyev JN, et al
     Impact of pelvic radiotherapy for prostate cancer on global metabolic profiles and microbiota-driven gastrointestinal late side-effects: a longitudinal observational study.
     Int J Radiat Oncol Biol Phys. 2021 Aug 2. pii: S0360-3016(21)02626.
     PubMed     Abstract available
     
     
     
119. LEITE ETT, Ramos CCA, Moraes FY
     In Reply to Fiorino et al.
     Int J Radiat Oncol Biol Phys. 2021;110:1549-1550.
     PubMed    
     
     
     
120. ARAI TJ, Yang DM, Campbell JW 3rd, Chiu T, et al
     Oxygen-Sensitive MRI: A Predictive Imaging Biomarker for Tumor Radiation Response?
     Int J Radiat Oncol Biol Phys. 2021;110:1519-1529.
     PubMed     Abstract available
     
     
     
121. PRASANNA PG, Rawojc K, Guha C, Buchsbaum JC, et al
     Normal Tissue Injury Induced by Photon and Proton Therapies: Gaps and Opportunities.
     Int J Radiat Oncol Biol Phys. 2021;110:1325-1340.
     PubMed     Abstract available
     
     
     July 2021
122. PARZEN JS, Hamstra DA
     Patient-Reported Quality of Life During Prostate Cancer Radiation Therapy: Insights Into the Patient Experience.
     Int J Radiat Oncol Biol Phys. 2021;110:1129-1131.
     PubMed    
     
     
     
123. CHOUDHURY A, Henry Md Frcr A, Mitin Md PhD T, Chen Md Mph R, et al
     Photons, Protons, SBRT, Brachytherapy-What Is Leading the Charge for the Management of Prostate Cancer? A Perspective From the GU Editorial Team.
     Int J Radiat Oncol Biol Phys. 2021;110:1114-1121.
     PubMed    
     
     
     
124. EFSTATHIOU JA, Kamran SC, Spratt DE
     Protons Versus Photons for Prostate Cancer: An Answer That Is Long Overdue and Coming.
     Int J Radiat Oncol Biol Phys. 2021;110:1098-1100.
     PubMed    
     
     
     
125. PARKER C
     Timing of Postoperative Radiation Therapy After Radical Prostatectomy.
     Int J Radiat Oncol Biol Phys. 2021;110:1132-1134.
     PubMed    
     
     
     
126. YANG Y, Vargas CE, Bhangoo RS, Wong WW, et al
     Exploratory Investigation of Dose-Linear Energy Transfer (LET) Volume Histogram (DLVH) for Adverse Events Study in Intensity Modulated Proton Therapy (IMPT).
     Int J Radiat Oncol Biol Phys. 2021;110:1189-1199.
     PubMed     Abstract available
     
     
     
127. SCHUMACHER O, Luo H, Taaffe DR, Galvao DA, et al
     Effects of exercise during radiotherapy on physical function and treatment-related side effects in men with prostate cancer: a systematic review and meta-analysis.
     Int J Radiat Oncol Biol Phys. 2021 Jul 8. pii: S0360-3016(21)00841.
     PubMed     Abstract available
     
     
     
128. BERTHOLD J, Khamfongkhruea C, Petzoldt J, Thiele J, et al
     First-in-human validation of CT-based proton range prediction using prompt gamma imaging in prostate-cancer treatments.
     Int J Radiat Oncol Biol Phys. 2021 Jul 3. pii: S0360-3016(21)00843.
     PubMed     Abstract available
     
     
     
129. KISHAN AU, Collins SP
     Quality of Life After Prostate Cancer Treatment.
     Int J Radiat Oncol Biol Phys. 2021;110:727-730.
     PubMed    
     
     
     
130. MOHAMAD O, Feng F
     Treating Localized High-Risk Prostate Cancer: Do All Roads Lead to Rome?
     Int J Radiat Oncol Biol Phys. 2021;110:634-635.
     PubMed    
     
     
     
131. BELKACEMI Y, Coraggio G, Loganadane G
     Management Strategy of High-Risk Localized Prostate Cancer: Is there a Transatlantic Consensus?
     Int J Radiat Oncol Biol Phys. 2021;110:631-632.
     PubMed    
     
     
     
132. RANS K, De Meerleer G, Joniau S, Baten A, et al
     In Regard to Zelefsky et al.
     Int J Radiat Oncol Biol Phys. 2021;110:910-911.
     PubMed    
     
     
     
133. WALSHAW RC, Hoskin PJ, Choudhury A
     Can Hypofractionation and Immune Modulation Coexist?
     Int J Radiat Oncol Biol Phys. 2021;110:742-744.
     PubMed    
     
     
     
134. WALLIS CJD, Klotz L, Satkunasivam R, Klaassen Z, et al
     Not So "Active" Surveillance.
     Int J Radiat Oncol Biol Phys. 2021;110:716-717.
     PubMed    
     
     
     
135. SHORTALL J, Palma G, Mistry H, Vasquez Osorio E, et al
     Flogging a Dead Salmon? Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials.
     Int J Radiat Oncol Biol Phys. 2021;110:696-699.
     PubMed    
     
     
     
136. CHEN RC
     A Trans-Atlantic Voyage of Extended ADT With Local Radiation.
     Int J Radiat Oncol Biol Phys. 2021;110:633.
     PubMed    
     
     
     
137. VAN DAMS R, Jiang NY, Fuller DB, Loblaw A, et al
     Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients.
     Int J Radiat Oncol Biol Phys. 2021;110:731-737.
     PubMed     Abstract available
     
     
     
138. HSU IC, Rodgers JP, Shinohara K, Purdy J, et al
     Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate.
     Int J Radiat Oncol Biol Phys. 2021;110:700-707.
     PubMed     Abstract available
     
     
     June 2021
139. BRAND DH, Bruningk SC, Wilkins A, Fernandez K, et al
     Estimates of Alpha/Beta (alpha/beta) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.
     Int J Radiat Oncol Biol Phys. 2021;110:596-608.
     PubMed     Abstract available
     
     
     May 2021
140. NITHIYANANTHAN K, Creighton N, Currow D, Martin JM, et al
     Population-Level Uptake of Moderately Hypofractionated Definitive Radiotherapy in the Treatment of Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021 May 8. pii: S0360-3016(21)00460.
     PubMed     Abstract available
     
     
     
141. HARA D, Tao W, Totiger T, Pourmand A, et al
     Prostate Cancer Targeted X-ray Fluorescence Imaging via Gold Nanoparticles Functionalized with Prostate-Specific Membrane Antigen (PSMA).
     Int J Radiat Oncol Biol Phys. 2021 May 5. pii: S0360-3016(21)00459.
     PubMed     Abstract available
     
     
     
142. WANG K, Mavroidis P, Royce TJ, Falchook AD, et al
     Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response.
     Int J Radiat Oncol Biol Phys. 2021;110:237-248.
     PubMed     Abstract available
     
     
     April 2021
143. NABID A, Carrier N, Vigneault E, Van Nguyen T, et al
     OPTIMIZING TREATMENT IN INTERMEDIATE RISK PROSTATE CANCER: SECONDARY ANALYSIS OF A RANDOMIZED PHASE III TRIAL.
     Int J Radiat Oncol Biol Phys. 2021 Apr 23. pii: S0360-3016(21)00373.
     PubMed     Abstract available
     
     
     
144. MASTERS SC, Hofling AA, Gorovets A, Marzella L, et al
     FDA Approves Ga 68 PSMA-11 for Prostate Cancer Imaging.
     Int J Radiat Oncol Biol Phys. 2021 Apr 12. pii: S0360-3016(21)00357.
     PubMed    
     
     
     
145. YAMAZAKI H, Suzuki G, Aibe N, Yoshida K, et al
     Posterior Margins in Prostate Cancer Radiation Therapy.
     Int J Radiat Oncol Biol Phys. 2021;109:1657-1658.
     PubMed    
     
     
     
146. MITCHELL D, Jain S
     Brachytherapy Boost in Prostate Cancer: What Does Observational Data Add to the Debate?
     Int J Radiat Oncol Biol Phys. 2021;109:1230-1231.
     PubMed    
     
     
     
147. LEITE ETT, Ramos CCA, Ribeiro VAB, Salvajoli BP, et al
     Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
     Int J Radiat Oncol Biol Phys. 2021;109:1263-1270.
     PubMed     Abstract available
     
     
     
148. FU SY, Chen FH, Wang CC, Yu CF, et al
     Role of Myeloid-Derived Suppressor Cells in High-Dose-Irradiated TRAMP-C1 Tumors: A Therapeutic Target and an Index for Assessing Tumor Microenvironment.
     Int J Radiat Oncol Biol Phys. 2021;109:1547-1558.
     PubMed     Abstract available
     
     
     
149. ROBIN S, Jolicoeur M, Palumbo S, Zilli T, et al
     Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy.
     Int J Radiat Oncol Biol Phys. 2021;109:1243-1253.
     PubMed     Abstract available
     
     
     March 2021
150. FOLKERT MR, Zelefsky MJ, Hannan R, Desai NB, et al
     A Multi-Institutional Phase II Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer.
     Int J Radiat Oncol Biol Phys. 2021 Mar 19. pii: S0360-3016(21)00285.
     PubMed     Abstract available
     
     
     
151. MAGLI A, Farneti A, Faiella A, Ferriero M, et al
     Toxicity at 1 year after Stereotactic Body Radiotherapy in 3 Fractions for Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021 Mar 18. pii: S0360-3016(21)00287.
     PubMed     Abstract available
     
     
     
152. BUSZEK SM, Ludmir EB, Grosshans DR, McAleer MF, et al
     Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.
     Int J Radiat Oncol Biol Phys. 2021;109:718-725.
     PubMed     Abstract available
     
     
     
153. SHAHI J, Poon I, Ung YC, Tsao M, et al
     Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
     Int J Radiat Oncol Biol Phys. 2021;109:764-774.
     PubMed     Abstract available
     
     
     February 2021
154. BUBLEY GJ, Kaplan I, Bhatt R, Taplin ME, et al
     Phase II study of Enzalutamide with radiation therapy for intermediate risk prostate cancer: A phase 2 study.
     Int J Radiat Oncol Biol Phys. 2021 Feb 23. pii: S0360-3016(21)00205.
     PubMed     Abstract available
     
     
     
155. KUBES J, Haas A, Vondracek V, Andrlik M, et al
     Ultra-hypofractionated proton radiotherapy in the treatment of low- and intermediate-risk prostate cancer - 5-years outcomes.
     Int J Radiat Oncol Biol Phys. 2021 Feb 12. pii: S0360-3016(21)00189.
     PubMed     Abstract available
     
     
     
156. VAPIWALA N, Wong JK, Handorf E, Paly J, et al
     A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity-Modulated Radiation Therapy in Early Stage Prostate Cancer Patients.
     Int J Radiat Oncol Biol Phys. 2021 Feb 1. pii: S0360-3016(21)00117.
     PubMed     Abstract available
     
     
     
157. SUD S, Gerringer BC, Wacaser B, Tan X, et al
     Under-ascertainment of clinically-meaningful symptoms during prostate cancer radiation therapy - does this vary by patient characteristics?
     Int J Radiat Oncol Biol Phys. 2021 Feb 1. pii: S0360-3016(21)00108.
     PubMed     Abstract available
     
     
     January 2021
158. ROY S, Grimes S, Morgan SC, Eapen L, et al
     Patient-reported Outcomes from a Phase III Randomized Controlled Trial Exploring Optimal Sequencing of Short-term Androgen Deprivation Therapy with Prostate Radiotherapy in Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021 Jan 29. pii: S0360-3016(21)00092.
     PubMed     Abstract available
     
     
     
159. CHEN RC, Prime SG, Basak R, Moon DH, et al
     Receipt of guideline-recommended surveillance in a population-based cohort of active surveillance prostate cancer patients.
     Int J Radiat Oncol Biol Phys. 2021 Jan 13. pii: S0360-3016(21)00034.
     PubMed     Abstract available
     
     
     December 2020
160. GARIN O, Suarez JF, Guedea F, Pont A, et al
     Comparative Effectiveness Research in Localized Prostate Cancer: a 10-Year follow-up Cohort Study.
     Int J Radiat Oncol Biol Phys. 2020 Dec 31. pii: S0360-3016(20)34728.
     PubMed     Abstract available
     
     
     
161. CHEN WC, Li Y, Lazar A, Altan A, et al
     Stereotactic body radiotherapy and high-dose rate brachytherapy boost in combination with intensity modulated radiotherapy for localized prostate cancer: a single-institution propensity score matched analysis.
     Int J Radiat Oncol Biol Phys. 2020 Dec 29. pii: S0360-3016(20)34730.
     PubMed     Abstract available
     
     
     
162. TANG C, Lei X, Smith GL, Pan HY, et al
     Influence of Geography on Prostate Cancer Treatment.
     Int J Radiat Oncol Biol Phys. 2020 Dec 11. pii: S0360-3016(20)34595.
     PubMed     Abstract available
     
     
     
163. PARRY MG, Nossiter J, Sujenthiran A, Cowling TE, et al
     Impact of high-dose rate and low-dose rate brachytherapy boost on toxicity, functional and cancer outcomes in patients receiving external beam radiation therapy for prostate cancer: a national population-based study.
     Int J Radiat Oncol Biol Phys. 2020 Dec 3. pii: S0360-3016(20)34545.
     PubMed     Abstract available
     
     
     
164. DEE EC, Muralidhar V, Arega MA, Kishan AU, et al
     Factors influencing non-completion of radiotherapy among men with localized prostate cancer.
     Int J Radiat Oncol Biol Phys. 2020 Dec 1. pii: S0360-3016(20)34604.
     PubMed     Abstract available
     
     
     
165. JANI A, Schreibmann E, Goyal S, Raghuveer H, et al
     Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine ((18)F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2020;108:1397.
     PubMed    
     
     
     
166. MARCELLO M, Denham JW, Kennedy A, Haworth A, et al
     Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials.
     Int J Radiat Oncol Biol Phys. 2020;108:1304-1318.
     PubMed     Abstract available
     
     
     November 2020
167. KOONTZ BF, Hoffman KE, Halabi S, Healy P, et al
     Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for Men with High and Intermediate Risk Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2020 Nov 28. pii: S0360-3016(20)34599.
     PubMed     Abstract available
     
     
     
168. WAGES NA, Sanders JC, Smith A, Wood S, et al
     Hypofractionated post-prostatectomy radiotherapy for prostate cancer to reduce toxicity and improve patient convenience: A Phase I/II trial.
     Int J Radiat Oncol Biol Phys. 2020 Nov 20. pii: S0360-3016(20)34497.
     PubMed     Abstract available
     
     
     
169. SPENCER KL, Tree AC
     Commentary on Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2020;108:927-929.
     PubMed    
     
     
     
170. DESAI NB, Garant A, Hannan R, Folkert MR, et al
     Evolving Brachytherapy Boost in Prostate Cancer in the Era of Hypofractionation.
     Int J Radiat Oncol Biol Phys. 2020;108:914-916.
     PubMed    
     
     
     
171. BOHMER D, Hocht S, Wiegel T
     Moving Beyond the Hazard Ratio to Personalized Therapy: Is it Prime Time?
     Int J Radiat Oncol Biol Phys. 2020;108:903-904.
     PubMed    
     
     
     
172. SHI J, Xu K, Keyvanloo A, Udayakumar TS, et al
     A Multimodality Image Guided Precision Radiation Research Platform: Integrating X-ray, Bioluminescence, and Fluorescence Tomography With Radiation Therapy.
     Int J Radiat Oncol Biol Phys. 2020;108:1063-1072.
     PubMed     Abstract available
     
     
     
173. TABRIZI S, Alshalalfa M, Mahal BA, Davicioni E, et al
     Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors.
     Int J Radiat Oncol Biol Phys. 2020;108:936-940.
     PubMed     Abstract available
     
     
     
174. TAKAGI M, Demizu Y, Fujii O, D KT, et al
     Proton Therapy for Localized Prostate Cancer: Long-term Results in 2,021 Patients.
     Int J Radiat Oncol Biol Phys. 2020 Nov 10. pii: S0360-3016(20)34493.
     PubMed     Abstract available
     
     
     
175. GOGINENI E, Rana Z, Soberman D, Sidiqi B, et al
     Biochemical control and toxicity outcomes of SBRT vs LDR brachytherapy in the treatment of low and intermediate risk prostate cancer.
     Int J Radiat Oncol Biol Phys. 2020 Nov 7. pii: S0360-3016(20)34489.
     PubMed     Abstract available
     
     
     
176. BERK L, Lopez Alfonso JC
     Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer In Regard to Vogelius et al.
     Int J Radiat Oncol Biol Phys. 2020;108:834.
     PubMed    
     
     
     
177. THOMPSON AB, Hamstra DA
     Rectal Spacer Usage with Proton Radiation Therapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2020;108:644-648.
     PubMed    
     
     
     
178. VOGELIUS IR, Bentzen SM
     In Reply to Berk and Alfonso.
     Int J Radiat Oncol Biol Phys. 2020;108:834-835.
     PubMed    
     
     
     
179. GUTIONTOV SI, Pitroda SP, Weichselbaum RR
     Oligometastasis: Past, Present, Future.
     Int J Radiat Oncol Biol Phys. 2020;108:530-538.
     PubMed     Abstract available
     
     
     
180. MAO X, Pineau J, Keyes R, Enger SA, et al
     RapidBrachyDL: Rapid Radiation Dose Calculations in Brachytherapy Via Deep Learning.
     Int J Radiat Oncol Biol Phys. 2020;108:802-812.
     PubMed     Abstract available
     
     
     October 2020
181. HOFFMAN KE
     Wait and Hurry Up: Radiation Therapy for Prostate Cancer During the COVID-19 Pandemic.
     Int J Radiat Oncol Biol Phys. 2020;108:340.
     PubMed    
     
     
     
182. LEEMAN JE, Nguyen PL
     Less Is More During COVID 19.
     Int J Radiat Oncol Biol Phys. 2020;108:339.
     PubMed    
     
     
     
183. SPRATT DE
     Cancer Treatment Decision-Making During the COVID-19 Pandemic: Data Over Opinion.
     Int J Radiat Oncol Biol Phys. 2020;108:338-339.
     PubMed    
     
     
     
184. MOHAMAD O, Roach M 3rd
     Delaying Dilemmas: Coronavirus Complications Impacting the Management of Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2020;108:337.
     PubMed    
     
     
     
185. LING DC, Vargo JA, Beriwal S
     Breast, Prostate, and Rectal Cancer: Should 5-5-5 Be a New Standard of Care?
     Int J Radiat Oncol Biol Phys. 2020;108:390-393.
     PubMed    
     
     
     
186. ZAORSKY NG
     Prostate and Pelvis on Pause Pending a Pandemic.
     Int J Radiat Oncol Biol Phys. 2020;108:341-342.
     PubMed    
     
     
     
187. KOONTZ BF
     Through COVID-Colored Glasses: New Perspectives on Same Data.
     Int J Radiat Oncol Biol Phys. 2020;108:338.
     PubMed    
     
     
     September 2020
188. SANDERS JW, Venkatesan AM, Levitt CA, Bathala T, et al
     Fully balanced SSFP without an endorectal coil for post-implant QA of MRI-assisted radiosurgery (MARS) of prostate cancer: a prospective study.
     Int J Radiat Oncol Biol Phys. 2020 Sep 24. pii: S0360-3016(20)34342.
     PubMed     Abstract available
     
     
     
189. SPRATT DE, Tward JD
     Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy.
     Int J Radiat Oncol Biol Phys. 2020 Sep 11. pii: S0360-3016(20)31252.
     PubMed    
     
     
     
190. ROYCE TJ, Mavroidis P, Wang K, Falchook AD, et al
     Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2020 Sep 5. pii: S0360-3016(20)34102.
     PubMed     Abstract available
     
     
     
191. 
     Erratum to: Pollack A, Chinea FM, Bossart E, Kwon D, Abramowitz MC, Lynne C, Jorda M, Marples B, Patel VN, Wu XD, Reis I, Studenski MT, Casillas J, Stoyanova R. Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Rad
     Int J Radiat Oncol Biol Phys. 2020;108:328.
     PubMed    
     
     
     August 2020
192. HALL WA, Paulson E, Davis BJ, Spratt DE, et al
     NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2020 Aug 27. pii: S0360-3016(20)34124.
     PubMed     Abstract available
     
     
     
193. DEEK MP, Taparra K, Dao D, Chan L, et al
     Patterns of Recurrence and Modes of Progression Following Metastasis Directed Therapy in Oligometastatic Castration Sensitive Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2020 Aug 13. pii: S0360-3016(20)34120.
     PubMed     Abstract available
     
     
     
194. PALY J, Horwitz EM
     Less Is More: Treatment of Locally Advanced Small Cell Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2020;107:865-866.
     PubMed    
     
     
     
195. DALWADI SM, Zhu A
     Big Small Cell Dilemma.
     Int J Radiat Oncol Biol Phys. 2020;107:863-864.
     PubMed    
     
     
     
196. ABU-GHEIDA I, Bathala TK, Maldonado JA, Khan M, et al
     Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers.
     Int J Radiat Oncol Biol Phys. 2020;107:982-985.
     PubMed     Abstract available
     
     
     July 2020
197. PARRY MG, Nossiter J, Cowling TE, Sujenthiran A, et al
     Toxicity of pelvic lymph node irradiation with intensity modulated radiation therapy for high-risk and locally advanced prostate cancer: a national population-based study using patient-reported outcomes.
     Int J Radiat Oncol Biol Phys. 2020 Jul 24. pii: S0360-3016(20)31450.
     PubMed     Abstract available
     
     
     
198. MITIN T, Choudhury A
     Flattening the Curve of Prostate Cancer Progression: Accurate Detection and Safe Ablation.
     Int J Radiat Oncol Biol Phys. 2020;107:609-612.
     PubMed    
     
     
     
199. WANG Y, Chen H
     In Reply to Ghadjar et al.
     Int J Radiat Oncol Biol Phys. 2020;107:856.
     PubMed    
     
     
     
200. MYLONA E, Ebert M, Kennedy A, Joseph D, et al
     Rectal and Urethro-vesical Subregions for Toxicity Prediction After Prostate Cancer Radiotherapy: validation of voxel-based models in an independent population.
     Int J Radiat Oncol Biol Phys. 2020 Jul 13. pii: S0360-3016(20)31417.
     PubMed     Abstract available
     
     
     
201. BERGAMIN S, Eade T, Kneebone A, Booth J, et al
     Interim results of a prospective PSMA-directed focal stereotactic re-irradiation trial for locally recurrent prostate cancer.
     Int J Radiat Oncol Biol Phys. 2020 Jul 10. pii: S0360-3016(20)31412.
     PubMed     Abstract available
     
     
     
202. SANDERS JW, Lewis GD, Thames HD, Kudchadker RJ, et al
     Machine segmentation of pelvic anatomy in MRI-assisted radiosurgery (MARS) for prostate cancer brachytherapy.
     Int J Radiat Oncol Biol Phys. 2020 Jul 4. pii: S0360-3016(20)31396.
     PubMed     Abstract available
     
     
     
203. VAN SCHIE MA, Janssen TM, Eekhout D, Walraven I, et al
     Knowledge-based assessment of focal dose escalation treatment plans in prostate cancer.
     Int J Radiat Oncol Biol Phys. 2020 Jul 3. pii: S0360-3016(20)31392.
     PubMed     Abstract available
     
     
     June 2020
204. ROY S, Grimes S, Eapen L, Spratt DE, et al
     Impact of Sequencing of Androgen Suppression and Radiotherapy on Testosterone Recovery in Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2020 Jun 18. pii: S0360-3016(20)31258.
     PubMed     Abstract available
     
     
     
205. PARIKH NR, Kishan AU, Kane N, Diaz-Perez S, et al
     Phase I Trial of Stereotactic Body Radiotherapy Neoadjuvant to Radical Prostatectomy for Patients with High-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2020 Jun 17. pii: S0360-3016(20)31251.
     PubMed     Abstract available
     
     
     
206. PARIKH NR, Chang EM, Nickols NG, Rettig MB, et al
     Cost-effectiveness of metastasis-directed therapy in oligorecurrent hormone-sensitive prostate cancer.
     Int J Radiat Oncol Biol Phys. 2020 Jun 13. pii: S0360-3016(20)31250.
     PubMed     Abstract available
     
     
     
207. JACCARD M, Zilli T, Dubouloz A, Escude L, et al
     Urethra-sparing stereotactic body radiotherapy for prostate cancer: quality assuranceof a randomized phase II trial.
     Int J Radiat Oncol Biol Phys. 2020 Jun 11. pii: S0360-3016(20)31242.
     PubMed     Abstract available
     
     
     
208. KOLLMEIER MA, McBride S, Varghese M, Debonis D, et al
     Low dose rate brachytherapy combined with ultra-hypofractionated radiation therapy for clinically localized, intermediate-risk prostate cancer: Results from a prospective trial.
     Int J Radiat Oncol Biol Phys. 2020 Jun 4. pii: S0360-3016(20)31189.
     PubMed    
     
     
     
209. 
     Erratum to: Liu W, Zukotynski K, Emmett L, Chung HT, Chung P, Wolfson R, Rachinsky I, Kapoor A, Metser U, Loblaw A, Morton G, Sexton T, Lock M, Helou J, Berlin A, Boylan C, Archer S, Pond GR, Bauman G. A Prospective Study of 18F-DCFPyL PSMA PET/CT Res
     Int J Radiat Oncol Biol Phys. 2020;107:390.
     PubMed    
     
     
     
210. YUCE SARI S, Elmali A, Arslan S, Ozyigit G, et al
     In Regard to Aksnessaetheret al.
     Int J Radiat Oncol Biol Phys. 2020;107:387-388.
     PubMed    
     
     
     
211. CHIN S, Fatimilehin A, Walshaw R, Argarwal A, et al
     Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure.
     Int J Radiat Oncol Biol Phys. 2020;107:288-296.
     PubMed     Abstract available
     
     
     May 2020
212. GHADJAR P, Zwahlen DR, Hayoz S, Aebersold DM, et al
     In Regard to Qi et al.
     Int J Radiat Oncol Biol Phys. 2020;107:224-225.
     PubMed    
     
     
     
213. GUNTHER JR
     Involved-Site Radiation Therapy if Minimal Toxicity.
     Int J Radiat Oncol Biol Phys. 2020;107:20-21.
     PubMed    
     
     
     
214. ALAYED Y, Davidson M, Liu S, Chu W, et al
     Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective Trials.
     Int J Radiat Oncol Biol Phys. 2020;107:136-142.
     PubMed     Abstract available
     
     
     April 2020
215. QIN H, Zhang V, Bok RA, Santos RD, et al
     Simultaneous metabolic and perfusion imaging using hyperpolarized (13)C MRI can evaluate early and dose-dependent responses to radiotherapy in a prostate cancer mouse model.
     Int J Radiat Oncol Biol Phys. 2020 Apr 24. pii: S0360-3016(20)31042.
     PubMed     Abstract available
     
     
     
216. MCCLELLAND S 3RD, Petereit DG
     The Advanced Alternative Payment Model: Catalyst for Prostate Brachytherapy Adoption?
     Int J Radiat Oncol Biol Phys. 2020;106:1104-1105.
     PubMed    
     
     
     
217. WILKINS A, Naismith O, Brand D, Fernandez K, et al
     Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation.
     Int J Radiat Oncol Biol Phys. 2020;106:928-938.
     PubMed     Abstract available
     
     
     March 2020
218. KEALL P, Nguyen DT, O'Brien R, Hewson E, et al
     Real-Time Image-Guided Ablative Prostate Cancer Radiation Therapy: Results from the TROG 15.01 SPARK Trial.
     Int J Radiat Oncol Biol Phys. 2020 Mar 29. pii: S0360-3016(20)30937.
     PubMed     Abstract available
     
     
     
219. ACHARD V, Zilli T
     In Regard to Qi et al.
     Int J Radiat Oncol Biol Phys. 2020;106:887-888.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: